CDEX Inc. (OTCBB:CEXI): An article published in the August issue of the Association of Perioperative Registered Nurses (AORN) Journal documents the benefits of CDEX’s Enhanced Photoemission Spectroscopy Technology in reducing narcotics diversion in the healthcare community. AORN J 88 (August 2008) 249-252. (C) AORN, Inc, 2008. http://www.aornjournal.org/article/S0001-2092(08)00258-5/abstract. The AORN Journal publication conclusion is similar to an earlier American Journal of Health-System Pharmacists peer-reviewed article detailing an 18-month independent study of the ValiMed(TM) Medication Validation System. Am J Health-Syst Pharm — Vol 65, pp 49-54, Jan 1, 2008.
“Drug diversion is an ongoing problem in health care settings,” said Dr. Kevin B. Sharer, MD, MBA, CPE and author of the AORN Journal article. “Records of the flow of controlled substances are kept by various accounting systems, but these systems can be inaccurate because the returned medications rarely are tested to verify that they have not been diluted or replaced. For example, fentanyl is a potent narcotic that is administered frequently in hospitals for the relief of pain as an adjunct to anesthesia in surgical procedures. It is diverted primarily from operating rooms through product substitution or outright theft, resulting in the potential under dosing of patients and falsifying of records,” continued Dr. Sharer. “The ValiMed System technology provides a quick and relatively inexpensive solution to this problem.”
The ValiMed Medication Validation System uses Enhanced Photoemission Spectroscopy to quickly validate high-risk medication admixtures such as returned narcotics to provide an increased level of patient safety. ValiMed compares a medication’s spectroscopic signature to the expected signature from the CDEX Medication Signature Library and returns an easy to understand “validated” or “not validated” result, requiring no user interpretation.
About CDEX
CDEX is a technology development company, currently manufacturing and globally distributing advanced chemical detection products, based on its patented Enhanced Photoemission Spectroscopy technologies. The company provides unique solutions to the challenges of identifying substances in difficult to monitor environments. CDEX technologies are being adapted to market needs for medication validation, hazardous chemicals detection, and brand protection through analysis of counterfeit substances. CDEX is currently organized to serve two critical markets — Medication Safety and Security. The ValiMed System is providing life-saving validation of high-risk medications in healthcare facilities and pharmacies. The ID2 Meth Scanner(TM) is a revolutionary new tool in the global battle against the growing scourge of methamphetamine abuse and its toxic impact on the general public. Corporate headquarters and R&D facilities are located in Tucson, Arizona with international offices in Paris, France. For more information, visit www.CDEXInc.com and www.valimed.com or contact Pascal Pouligny ([email protected]) at 520-745-5172.
Any Non-Historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as “expects,””plans,””may,””anticipates,””believes,””should,””intends,””estimates,” and other similar words. These statements pose risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the Protection of intellectual property and proprietary information, and other risks detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.
Comments